Document Detail


Effectiveness and Safety of Tapentadol Prolonged Release for Severe, Chronic Low Back Pain With or Without a Neuropathic Pain Component: Results of an Open-label Phase 3b Study.
MedLine Citation:
PMID:  22443293     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Abstract Objective: This open-label, phase 3b study evaluated the effectiveness and tolerability of tapentadol prolonged release and tapentadol immediate release (for acute pain episodes) for severe, chronic low back pain with or without a neuropathic pain component that was inadequately managed in patients taking World Health Organization (WHO) Step I or II analgesics or who were not regularly treated with analgesics. Research design and methods: Average baseline pain intensity was greater than 5 (11-point numerical rating scale-3 [NRS-3; 3-day average pain intensity]) with WHO Step I or II analgesics and greater than 6 with no regular analgesic regimen. WHO Step II analgesics were discontinued before starting study treatment; WHO Step I analgesics or co-analgesics were continued at the same dose. Patients received tapentadol prolonged release (50-250 mg bid) during a 5-week titration and 7-week maintenance period. Tapentadol immediate release was permitted for acute pain episodes (tapentadol prolonged release and immediate release maximum combined dose, ≤500 mg/day). The painDETECT questionnaire was used to define subsets of patients based on the probability of a neuropathic pain component to their low back pain as "negative," "unclear," or "positive." Clinical trial registration: NCT00983385. Main outcome measure: The primary endpoint was the change from baseline to Week 6 in average pain intensity (NRS-3), using the last observation carried forward to impute missing scores. Results: In the painDETECT negative (n = 49) and unclear/positive (n = 126) subsets, respectively, mean (SD) changes in pain intensity from baseline to Week 6 were -2.4 (2.18) and -3.0 (2.07; both P <0.0001). Among patients who had not received prior WHO Step II treatment, lower doses of tapentadol prolonged release were generally required with increasing likelihood of a neuropathic pain component. Based on the painDETECT questionnaire and the Neuropathic Pain Symptom Inventory (NPSI), tapentadol prolonged release treatment was also associated with significant improvements in neuropathic pain symptoms, with decreases in the number of pain attacks and the duration of spontaneous pain in the last 24 hours in patients with low back pain with a neuropathic pain component (painDETECT unclear or positive score at baseline or screening). The most common treatment-emergent adverse events (incidence ≥10%, n = 176) were nausea, dizziness, headache, dry mouth, fatigue, constipation, diarrhea, nasopharyngitis, and somnolence. Conclusions: Tapentadol prolonged release was well tolerated and effective for managing severe, chronic low back pain with or without a neuropathic pain component.
Authors:
Ilona Steigerwald; Matthias Müller; Anthony Davies; Daniel Samper; Rainer Sabatowski; Ralf Baron; Sylvie Rozenberg; Anna Szczepanska-Szerej; Antonio Gatti; Hans G Kress
Related Documents :
22551663 - The pain of social disconnection: examining the shared neural underpinnings of physical...
22712503 - The effectiveness of a group-based acceptance and commitment additive therapy on rehabi...
11379273 - Facial pain: from animal models to functional neuroimaging studies.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-3-25
Journal Detail:
Title:  Current medical research and opinion     Volume:  -     ISSN:  1473-4877     ISO Abbreviation:  -     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-3-26     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0351014     Medline TA:  Curr Med Res Opin     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Equation Chapter 1 Section 1Modeling of Oxygen Transport and Cell Killing in Type II Photodynamic Th...
Next Document:  Enzymatic Synthesis of Galacto-Oligosaccharides in Organic-Aqueous Biphasic System by a Novel ?-Gala...